title: Semicarbazide-sensitive amine oxidase/vascular adhesion protein-1: a patent survey.
abstract: BACKGROUND
  Vascular adhesion protein-1 (VAP-1)/semicarbazide-sensitive amine oxidase (SSAO) is an adhesion protein involved in leukocyte trafficking and inflammatory processes, with a special amine oxidase activity. Inhibitors have been mainly developed for treating chronic inflammatory disorders. The utility of inhibitors as antiangiogenic agents in ophthalmological and oncological diseases is currently under evaluation. SSAO substrates may mimic several insulin effects, although their utility for the treatment of diabetes is still far from being fully understood.
  
  
  METHODS
  This paper reviews the patent literature of SSAO/VAP-1 inhibitors and substrates, for the period of 1990 - 2010. The current stage of SSAO/VAP-1-interacting agents published in patents is described, along with their chemical structures and pharmacological uses.
  
  
  CONCLUSIONS
  SSAO/VAP-1 is a promising anti-inflammatory target. Another important field for therapeutic application of these inhibitors may be ophthalmology, due to their antiangiogenic effects. SSAO substrates might also be of therapeutic value in the treatment of diabetes; however, more extensive research has to be undertaken to validate this approach.
authors.affiliation: Semmelweis University, Department of Organic Chemistry , Hőgyes Endre utca 7, 1092 Budapest , Hungary.
authors.forename: Petra
authors.initials: P
authors.lastname: Dunkel
authors.forename: Balázs
authors.initials: B
authors.lastname: Balogh
authors.forename: Rita
authors.initials: R
authors.lastname: Meleddu
authors.forename: Elias
authors.initials: E
authors.lastname: Maccioni
authors.forename: Klára
authors.initials: K
authors.lastname: Gyires
authors.forename: Péter
authors.initials: P
authors.lastname: Mátyus
mesh_terms: D006631:Amine Oxidase (Copper-Containing) / Q000037:antagonists & inhibitors*; D000818:Animals; D019138:Antibodies, Blocking / Q000494:pharmacology; D015815:Cell Adhesion Molecules / Q000037:antagonists & inhibitors*; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D006834:Hydrazines / Q000494:pharmacology; D007249:Inflammation / Q000188:drug therapy; D010330:Patents as Topic; D034741:RNA, Small Interfering / Q000494:pharmacology; D013379:Substrate Specificity; D013844:Thiazoles / Q000494:pharmacology
chemical_list: D019138:Antibodies, Blocking; D015815:Cell Adhesion Molecules; D004791:Enzyme Inhibitors; D006834:Hydrazines; D034741:RNA, Small Interfering; D013844:Thiazoles; C076668:AOC3 protein, human; D006631:Amine Oxidase (Copper-Containing)